Abstract: The present disclosure provides a cultivation method of morels and belongs to the technical field of cultivation of edible fungi. After nutrient contents that can be metabolized and utilized by morel mycelia are scientifically matched, sterilization treatment of exogenous nutrients is eliminated, and the exogenous nutrients are directly compressed for forming. Formed exogenous nutrient blocks and spawn is sowed and covered with soil, so as to realize a potential difference between “rich” and “poor” nutrients in a physical space. When the spawn germinate to form a mycelium network, the mycelia will enter a nutrient-rich exogenous nutrient area, secrete various extracellular enzymes to decompose and utilize these exogenous nutrient blocks, and transport them to a nutrient-poor mycelium network for storage, so as to complete nutrient assimilation and absorption, and reserve energy for later sexual reproduction.

Abstract: The present disclosure relates to a celastrol or a pharmaceutically acceptable salt thereof, and a use thereof in the manufacture of a medicament for preventing and/or treating a cholestatic liver disease or a liver fibrosis.

Abstract: The present disclosure provides a cultivation method of morels and belongs to the technical field of cultivation of edible fungi. After nutrient contents that can be metabolized and utilized by morel mycelia are scientifically matched, sterilization treatment of exogenous nutrients is eliminated, and the exogenous nutrients are directly compressed for forming. Formed exogenous nutrient blocks and spawn is sowed and covered with soil, so as to realize a potential difference between “rich” and “poor” nutrients in a physical space. When the spawn germinate to form a mycelium network, the mycelia will enter a nutrient-rich exogenous nutrient area, secrete various extracellular enzymes to decompose and utilize these exogenous nutrient blocks, and transport them to a nutrient-poor mycelium network for storage, so as to complete nutrient assimilation and absorption, and reserve energy for later sexual reproduction.

Abstract: The present disclosure relates to a celastrol or a pharmaceutically acceptable salt thereof, and a use thereof in the manufacture of a medicament for preventing and/or treating a cholestatic liver disease or a liver fibrosis.

Abstract: The invention provides a pharmaceutical composition for treating a respiratory disease, wherein the pharmaceutical composition comprises one or more components selected from picrinine, vallesamine, scholaricine, and 19-epischolaricine. The pharmaceutical composition has a good protective effect on the respiratory system, and can be used in treatment of a relevant disease.

Abstract: The invention provides a pharmaceutical composition for treating a respiratory disease, wherein the pharmaceutical composition comprises one or more components selected from picrinine, vallesamine, scholaricine, and 19-epischolaricine. The pharmaceutical composition has a good protective effect on the respiratory system, and can be used in treatment of a relevant disease.

Abstract: The invention relates to a derivative of 15-oxospiramilacton, particularly to a compound of Formula I or II, or an isomer, a solvate or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the compound as pharmaceutically active ingredient, a method for preparing the same, and use thereof in manufacture of an anti-tumor agent. The derivative of 15-oxospiramilactone of the invention have an activity against multiple tumor cell lines, and the anti-tumor activity is positively correlated to an activity inhibiting the Wnt signaling pathway.

Abstract: The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.

Abstract: Nitrogen-containing biphenyl compounds as represented by formula (I), pharmaceutically acceptable salts or derivatives thereof, pharmaceutical compositions, and preparation methods therefore, and anti-HIV-1 use of the compound. Each substituent group in formula (I) is as defined in the description.

Abstract: A low-molecular-weight fucosylated glycosaminoglycan (aTFG) containing 2,5-anhydrated talose, alditol, glycosylamine or N-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the aTFG, and use thereof for preventing and/or treating thrombotic diseases are provided. The aTFG has potent anticoagulant activity targeting at intrinsic coagulation factor Xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases.

Abstract: The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to method for preparing the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof, and the use of the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of cancers.

Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-? type I receptor (T?RI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as ?-smooth muscle actin (?-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-?1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.

Abstract: The invention relates to a use of an urushiol compound (code named GQ-5) in preparation of pharmaceutical compositions for inhibiting Smad3 phosphorylation. We verify that GQ-5 inhibited the interaction of Smad3 with TGF-? type I receptor (T?RI), inhibited subsequent phosphorylation of Smad3, reduced nuclear translocation of Smads complex, and suppressed the transcription of major fibrotic genes such as ?-smooth muscle actin (?-SMA), collagen I and fibronectin. Therefore, GQ-5 could be a potent and selective inhibitor of TGF-?1-induced Smad3 phosphorylation, and be used to prepare pharmaceutical compositions for inhibiting Smad3 phosphorylation.

Abstract: The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine.

Abstract: Nitrogen-containing biphenyl compounds as represented by formula (I), pharmaceutically acceptable salts or derivatives thereof, pharmaceutical compositions, and preparation methods therefore, and anti-HIV-1 use of the compound. Each substituent group in formula (I) is as defined in the description.

Abstract: The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to method for preparing the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof, and the use of the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of cancers.

Abstract: The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine.

Abstract: The present invention relates to concentricolide and its derivatives, a method for the preparation of the compound and its derivatives, a pharmaceutical composition containing concentricolide and its derivatives, and use of the compound and its derivatives for the treatment and prevention of infection caused by human immunodeficiency virus (HIV).